1.22
+0.08(+7.02%)
Currency In USD
| Previous Close | 1.14 |
| Open | 1.13 |
| Day High | 1.23 |
| Day Low | 1.13 |
| 52-Week High | 3.46 |
| 52-Week Low | 0.5 |
| Volume | 77,639 |
| Average Volume | 372,620 |
| Market Cap | 52.1M |
| PE | -1.31 |
| EPS | -0.93 |
| Moving Average 50 Days | 0.87 |
| Moving Average 200 Days | 1.32 |
| Change | 0.08 |
If you invested $1000 in Elutia Inc. (ELUT) since IPO date, it would be worth $84.14 as of March 04, 2026 at a share price of $1.22. Whereas If you bought $1000 worth of Elutia Inc. (ELUT) shares 5 years ago, it would be worth $83.28 as of March 04, 2026 at a share price of $1.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
GlobeNewswire Inc.
Feb 25, 2026 9:05 PM GMT
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after mark
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organiza